Carisma Therapeutics Inc [NASDAQ: CARM] closed the trading session at $13710000.0 on 2025-06-23. The day’s price range saw the stock hit a low of $0.409, while the highest price level was $0.4675.
The stocks have a year to date performance of -56.22 percent and weekly performance of -0.16 percent. The stock has been moved at -2.84 percent over the last six months. The stock has performed 156.34 percent around the most recent 30 days and changed 8.99 percent over the most recent 3-months.
If compared to the average trading volume of 13.71M shares, CARM reached to a volume of 15980038 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Carisma Therapeutics Inc [CARM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CARM shares is $1.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CARM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Carisma Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 12, 2024. The new note on the price target was released on December 10, 2024, representing the official price target for Carisma Therapeutics Inc stock. Previously, the target price had yet another raise to $6, while BTIG Research analysts kept a Buy rating on CARM stock.
CARM stock trade performance evaluation
Carisma Therapeutics Inc [CARM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.16. With this latest performance, CARM shares gained by 156.34% in over the last four-week period, additionally sinking by -2.84% over the last 6 months – not to mention a rise of 7.66% in the past year of trading.
Carisma Therapeutics Inc [CARM]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Carisma Therapeutics Inc [CARM] shares currently have an operating margin of -260.48% and a Gross Margin at 83.98%. Carisma Therapeutics Inc’s Net Margin is presently recorded at -254.28%.
Return on Equity for this stock declined to -113.13%, with Return on Assets sitting at -113.13%.
Earnings per share (EPS) analysis for Carisma Therapeutics Inc [CARM] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CARM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Carisma Therapeutics Inc go to 24.74%.
Carisma Therapeutics Inc [CARM]: Institutional Ownership
There are presently around $31.76%, or 43.96%% of CARM stock, in the hands of institutional investors. The top three institutional holders of CARM stocks are: VANGUARD GROUP INC with ownership of 1.45 million shares, which is approximately 3.4861%. TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, holding 1.25 million shares of the stock with an approximate value of $$1.9 million in CARM stocks shares; and TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, currently with $$1.28 million in CARM stock with ownership which is approximately 2.0269%.
